Loading stock…

Relay Therapeutics, Inc. (RLAY) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Relay Therapeutics, Inc.

RLAYMarket cap $3.93BPrice $17.9

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops cancer and genetic disease drugs by mapping how proteins move and shift shape, not just their static structure. This motion-based approach helped land a partnership with Genentech worth up to $1 billion.

In Bastion Portfolios?

52W Return+177%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+123%10

Revenue Forecast

Rev CAGR (1y)-76%1

Rev CAGR (3y)+18%9

Rev CAGR (5y)+98%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-2999%1

Net Income Margin-2764%1

Free Cash Flow Margin-2050%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-37%1

ROA-34%1

Earnings Stabilityna–

GEAR+VERY WEAK6

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV4.44

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-5.4%1

Dividend Yieldna–

Momentum

Short term

1 month return-6%4

3 month return-9%4

YTD return+112%10

Mid term

Price vs 52wHigh84%6

1 year return+194%10

Long term

3 year return+117%8

5 year return-36%2

Risk Shield

Price Risk

Beta2.01

Volatility65%2

Free Cash Flow

Free Cash Flow Margin-2050%1

Free Cash Flow Yield-5.4%1

Quality

ROCE-38%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

RLAYRelay Therapeutics

Revenue FY25$15M

GROWTH RATING↗

STRONG68 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+123%10

Revenue, next 1Y-76%1

Revenue, next 3Y, CAGR+18%9

Revenue, next 5Y, CAGR+98%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 68% of companies worldwide.

Revenue grew 123%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 18%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 98%/yr over five years.10/10

WATCH

Revenue grew 123%/yr over the last 3 years; forecasts see it cooling to 18%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE49 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-9%4

YTD return+112%10

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+194%10

3-year return+117%8

5-year return-36%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 194% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+112%).

WATCH

Average long-term results. Multi-year returns are middling (+117% over three years and -36% over five), roughly average for the market.

Returns sit at the market level over the past month (-6%) and over three months (-9%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Relay Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

RLAYRelay Therapeutics

Revenue FY25$15M

GROWTH RATING↗

STRONG68 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+123%10

Revenue, next 1Y-76%1

Revenue, next 3Y, CAGR+18%9

Revenue, next 5Y, CAGR+98%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 68% of companies worldwide.

Revenue grew 123%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 18%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 98%/yr over five years.10/10

WATCH

Revenue grew 123%/yr over the last 3 years; forecasts see it cooling to 18%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE49 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-9%4

YTD return+112%10

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+194%10

3-year return+117%8

5-year return-36%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 194% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+112%).

WATCH

Average long-term results. Multi-year returns are middling (+117% over three years and -36% over five), roughly average for the market.

Returns sit at the market level over the past month (-6%) and over three months (-9%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Relay Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community